Symbol | Exchange | Currency |
|---|
OKYO Pharma Limited operates as a preclinical biopharmaceutical company in the United Kingdom. Its preclinical development program includes OK-101 for the treatment of dry eyes, uveitis, and allergic conjunctivitis; and OK-201 to treat corneal neuropathic pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome (ARDS). OKYO Pharma Limited was incorporated in 2018 and is headquartered in London, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 14.91 | 14.93 | 14.50 | -0.01 | -0.10% | 13.57K | London | |||
| 47.09 | 47.38 | 46.83 | -0.61 | -1.28% | 16.94M | London | |||
| 49.87 | 50.00 | 47.55 | +0.95 | +1.94% | 1.13M | London | |||
| 884.00 | 896.60 | 868.00 | -22.60 | -2.49% | 111.18K | London | |||
| 236.40 | 237.01 | 234.69 | -3.00 | -1.25% | 34.07K | London | |||
| 22.95 | 24.20 | 22.90 | -1.15 | -4.77% | 164.35K | London | |||
| 982.40 | 989.20 | 981.20 | -24.60 | -2.44% | 1.01M | London | |||
| 37.85 | 37.85 | 37.85 | +0.75 | +2.00% | 1.50M | London | |||
| 115.00 | 115.00 | 115.00 | -2.00 | -1.71% | 281.39K | London | |||
| 295.00 | 295.00 | 295.00 | -12.50 | -4.10% | 3.50K | London | |||
| 49,660.00 | 49,750.00 | 49,700.00 | -300.0 | -0.60% | 847.00 | London | |||
| 81.23 | 83.80 | 82.40 | +1.20 | +1.48% | 6.53K | London | |||
| 12.13 | 12.13 | 12.13 | +0.63 | +5.49% | 230.59K | London | |||
| 162.70 | 163.70 | 159.65 | +0.35 | +0.22% | 881.30K | London | |||
| 125.54 | 126.89 | 122.63 | -0.60 | -0.48% | 1.80M | London |